Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23414683 | 0.88 | MEN1 (0.37) | GPR139MEN1KMT2AFADS1ENPP1 | |
| SCHEMBL23414926 | 0.88 | MEN1 (0.47) | MEN1KMT2AFADS1ENPP1MAPT | |
| SCHEMBL23414892 | 0.88 | ADORA3 (0.41) | MEN1KMT2AFADS1ENPP1KCNQ3 | |
| SCHEMBL23414599 | 0.87 | FADS1 (0.40) | GPR139MEN1KMT2ASCN5AFADS1 | |
| SCHEMBL23414705 | 0.87 | FADS1 (0.40) | MEN1KMT2ASCN5AFADS1ENPP1 | |
| SCHEMBL23414813 | 0.86 | KMT2A (0.39) | MEN1KMT2AFADS1ENPP1KCNQ3 | |
| SCHEMBL23414623 | 0.85 | CYP1A2 (0.39) | GPR139MEN1KMT2ASCN5A | |
| SCHEMBL23414546 | 0.85 | FADS1 (0.39) | MEN1KMT2AFADS1ENPP1KCNQ3 | |
| SCHEMBL23414618 | 0.85 | FADS1 (0.39) | MEN1KMT2AFADS1ENPP1KCNQ3 | |
| SCHEMBL29972816 | 0.85 | CYP1A2 (0.39) | GPR139MEN1KMT2ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4622648-A1 | SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS | Amgen Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| WO-2024112763-A9 | SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS | AMGEN INC. (US) | 2024-07-11 | — | — | WO | claimed |
| WO-2024112763-A1 | SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS | AMGEN INC. (US) | 2024-05-30 | — | — | WO | claimed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | claimed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | claimed |
| WO-2021108404-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | claimed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4622648-A1 | SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS | Amgen Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024112763-A1 | SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS | AMGEN INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021108404-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | GPR139 1442/4885MEN1 3962/4885KMT2A 3001/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | GPR139 1442/4885MEN1 3962/4885KMT2A 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.